Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Identification and development of vaccine candidates for Buruli Ulcer Disease (BURULIVAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Germany,Germany,Belgium,Switzerland,United Kingdom,Netherlands,France,Portugal,Germany,Ghana,Belgium,Germany,Germany,Benin,Congo, The Democratic Republic of the
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2013-05-31
Duration (months): 39.0
Total project cost (EUR): 6021315.2
EU funding (EUR): 4599983.0
Participants: 16
Project status: CLOSED

Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly affecting children. BUD, the third most common mycobacterial disease in immunocompetent humans after tuberculosis and leprosy, is most endemic in West Africa, but cases have been reported from more than 30 countries. BUD is a mutilating disease leading to severe disability. Treatment with antibiotics is possible but is long-lasting and requires injections, shows treatment failures and drug resistance may occur. A vaccine against M. ulcerans would protect persons at risk in highly endemic areas and could be used as a therapeutic vaccine to shorten duration of treatment and to prevent relapses. The general objective of BuruliVac is to identify and develop novel vaccine candidates suitable for translation into clinical application. This objective will be achieved by a multidisciplinary approach involving among others basic and applied research in immunology, bioinformatics, molecular genetics, tropical medicine, microbiology and clinical bacteriology. As currently no existing vaccine lead candidate is available, the consortium will identify and develop new vaccine candidates of different types, will evaluate them using bioinformatics, applied genomics and proteomics and will subject them to consecutive test systems. For evaluation of vaccine candidates regarding their application in humans, the consortium will also study the immune response and disease immunopathology to define correlates of protection. Essential pre-clinical testing in vitro and in vivo will select a small number of candidates that is amenable to be introduced into clinical studies.

Keywords: protein subunit vaccines,attenuated live vaccines,mycobacterium ulcerans,tropical medicine
Strategic Targets for 2020 - Collaboration Initiative on Biorefineries (STAR-COLIBRI)

Framework: FP7 — Cooperation
Programme: Nanosciences, Nanotechnologies, Materials and new Production Technologies - NMP
Destination: Integration
Action type: Coordination and support actions
Countries involved: Belgium,Germany,Germany,United Kingdom,Finland,France,Netherlands
Call:  (FP7-2009-BIOREFINERY_CSA, 2009)
Start date: 2009-11-01
End date: 2011-10-31
Duration (months): 24.0
Total project cost (EUR): 2410457.6
EU funding (EUR): 1951959.0
Participants: 11
Project status: CLOSED

For the first time in Europe a real critical mass along the whole value-chain, and in all aspects of the biorefinery concept, will be achieved by the close collaboration of five industry-driven European Technology Platforms, five excellent research partners with complementary expertise, and the International Civil Society Organisation IUCN, who will validate the impact on the global sustainability of the results. The collaboration in this Coordination and Support Action is called Star-COLIBRI, and its main objectives are to promote coordination and work to overcome fragmentation in the field of biorefineries research; to facilitate information exchange and cross-fertilization; to support break-through innovations by speeding up and facilitate industrial exploitation of research results. The Star-COLIBRI project will accomplish these targets by working in two parallel but mutually dependant processes: The first process has longer term objectives and it will provide a framework for collaborations and information exchange, common vision and a roadmap for 2020. It will also directly contribute to policy initiatives such as the European Lead Market Initiative on Bio-Based Products. The second process has shorter term objectives and aims to the immediate support and coordination of ongoing biorefinery research projects with potential high impact. The new strategy developed for this is called StarClustering. Better coordination of national research funding through an ERA-Net Liaisons Office will also be achieved.

Keywords: biorefinery,biomass,biobased products,bioenergy,biofuels,sustainable production
Fixed Dose Combination drugs for Secondary Cardiovascular Prevention (FOCUS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Spain,Italy,Spain,France,Argentina,Switzerland
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-07-01
End date: 2014-06-30
Duration (months): 48.0
Total project cost (EUR): 4812682.2
EU funding (EUR): 2999999.0
Participants: 9
Project status: CLOSED

Cardiovascular diseases (CVD) are the leading cause of death worldwide, and their incidence is increasing sharply in developing countries. Two insufficiently addressed factors contribute to increased morbidity and mortality, threatening the effectiveness of any health system: poor patient adherence to treatment, and limited access to medication in resource-poor countries and regions. To address these issues, FOCUS aims to test the Fixed-Dose-Combination (FDC) concept for CVD prevention and treatment in populations with diverse socio-economic characteristics. The FOCUS FDC pill developed by the consortium is a single-day pill containing three active components of well-demonstrated efficacy. It can be produced and administrated at a much lower cost than conventional multi-pill equivalents and is thus especially suitable for widespread use in resource-poor countries. The FDC pill will be tested in two complementary controlled clinical studies: a descriptive non-interventional study followed by an interventional randomized trial. The studies will analyze data collected at 40 clinical sites in Europe and 40 sites in three middle-income developing countries. FOCUS is an international collaboration between research institutes, clinicians, pharma industry, SMEs and scientific organisations. It aims to establish a proof of concept of FDC efficacy for secondary CVD prevention, and a better understanding of socio-economic factors that influence access and adherence to CVD treatment. Based on the project results FOCUS will publish recommendations for the use of this medication to improve patient adherence and access to CVD prevention medication in developing countries and beyond. A successful project will directly contribute to improved use of clinical research findings for treatment of CVD diseases and to creating equitable access to a more efficient CVD prevention medication for patients in developed and resource-poor countries.

Keywords: cardiovascular diseases,myocardial infarction,secondary prevention,treatment,treatment adherence,fixed-dose combination,developing countries,clinical trial,chronic diseases
Psychosocial fActors Relevant to BrAin DISorders in Europe (PARADISE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Germany,Spain,Italy,Switzerland,Switzerland,Belgium,United Kingdom,Poland,Finland
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2013-06-30
Duration (months): 42.0
Total project cost (EUR): 1675934.42
EU funding (EUR): 1482092.0
Participants: 10
Project status: CLOSED

The overall prevalence of brain disorders – both neurological and psychiatric – is very high in Europe. Although it is well known that the burden and costs of these disorders are high, there is evidence that the overall, personal, social and economic costs of brain disorders have been underestimated because of the lack of valid and reliable information regarding the full range of psychosocial difficulties that actually shape the lived experience of persons with these disorders and affect their quality of life. Current European data on psychosocial difficulties are derived from the diagnostic criteria of each disorder and so take the form of narrow ‘information silos’ that are neither comprehensive nor comparable across disorders. Distinct information silos means that treatment planning, treatment evaluation and outcome assessment ignores commonalities of psychosocial consequences across disorders, undermining treatment efficiency and effectiveness, and ultimately increasing the costs of health and social care provision. The coordination action called PARADISE has the general objective of coordinating the development of a comprehensive and cross-cutting or ‘horizontal epidemiology’ of psychosocial difficulties associated with brain disorders. Since a horizontal epidemiology accounts for the psychosocial difficulties that are actually experienced by people with brain disorders, independently of the brain disorder associated with them, it concentrates on what is more relevant to the lives of people with brain disorders. This leads to more effective intervention planning and management, and therefore to improved quality of life along the continuum of care, in the community, and across the life span. PARADISE coordinates the existing expertise in partners from eight European countries in relation to research literature, data documentation and analysis strategies for a representative range of brain disorders. These disorders are dementia, depression, epilepsy, migraine, multiple sclerosis, Parkinson’s Disease, schizophrenia, stroke and substance use disorders. PARADISE will pave the way to future investigations that more meaningfully track the trajectories of psychosocial difficulties of brain disorders.

Keywords: brain disorders,psycho-social disabling symptoms,functioning,disability,quality of life
Quality and costs of primary care in Europe (EUPRIMECARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Spain,Germany,Estonia,Finland,Italy,Lithuania,Hungary
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2012-12-31
Duration (months): 36.0
Total project cost (EUR): 3005110.35
EU funding (EUR): 2351535.0
Participants: 9
Project status: CLOSED

The overall objective of this project is to use research methods to describe different primary care models in Europe, assess their quality in different dimensions – particularly access, equity and satisfaction - and determine their cost. We will analyse variations of both quality and cost as they apply to specific organisational models in Europe, and will study the possible trade-offs between quality and costs in each model. Key research challenges will be the following: (i) to apply an innovative approach to identify and describe European primary care models, (ii) to develop and pilot a methodology to study relevant healthcare costs at macro and micro-level, and (iii) to combine surveys addressing perceptions of public and health professionals along with a review of clinical data to assess quality. The results of the project will develop, test and apply a valid framework for trans-national comparisons of quality atributes and costs with which to facilitate decision making concerning primary care models, the behaviour and delivery of primary care services. This framework will be an asset for those countries aiming at putting primary care at the centre of their healthcare model in terms of its quality, and in perspective with the total costs of healthcare provision and with the state of primary care in Europe. In summary, the core aim of the consortium is to inform policy decisions on primary care, giving explicit evidence of what measures can crucially be used to improve the overall quality of health systems, emphasizing their equity, evidence base, social cohesion, and sustainability as the values underlying the design of primary care models and its provision to European citizens.

Keywords: primary care,quality,costs,efficiency,developing research methods and tools,europe
Dosimetry and Health Effects of Diagnostic Applications of Radiopharmaceuticals with particular emphasis on the use in children and adolescents (PEDDOSE.NET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Coordination and support actions
Countries involved: Austria,France,Belgium,Germany,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-04-01
End date: 2012-01-31
Duration (months): 22.0
Total project cost (EUR): 602823.4
EU funding (EUR): 499581.0
Participants: 5
Project status: CLOSED

The aim of this proposal is to provide data on dosimetry and corresponding dose related risks when administering radiopharmaceuticals for diagnostic purposes in children and adults. The composition of the consortium ensures that contacts to other bodies such as the International Commission on Radiological Protection (ICRP), the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine or member state radiation protection agencies are provided in order to obtain up-to-date information on the developments in this field. In addition, data on imaging device-specific parameters and corresponding phantoms will be gathered in order to get information on potential dose reductions with emphasis on paediatric nuclear medicine procedures, and on computed tomography absorbed doses in hybrid scanners. If, as a result of the reviews, the need for additional clinical trials is identified, details for the set-up of such trials will be given. Finally, recommendations for weight-dependent minimum and maximum activities with particular emphasis on paediatric nuclear medicine will be developed. The dissemination of results will be coordinated by the European Institute for Biomedical Imaging Research (EIBIR) and undertaken with the help of the radiation protection authorities in individual member states and the European Association of Nuclear Medicine (EANM).

Keywords: dosimetry
Development of a strategic roadmap towards a large scale demonstration project in European logistics and supply chain security (LOGSEC)

Framework: FP7 — Cooperation
Programme: Security
Destination: Increasing the Security of citizens
Action type: Coordination and support actions
Countries involved: United Kingdom,Switzerland,Belgium,Spain,Poland,United Kingdom
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-04-01
End date: 2011-03-31
Duration (months): 12.0
Total project cost (EUR): 800047.14
EU funding (EUR): 753372.32
Participants: 8
Project status: CLOSED

The goal of the LOGSEC project is to develop a strategic roadmap for a large scale demonstration project in European logistics and supply chain security, characterised by adequate security for the benefit of business and governments, on low time-delay and other cost implications. A broad set of security policies, regulations, standards, technologies, procedural aspects, services, IPR-issues and links to other related projects will be assessed and evaluated during the project in close collaboration between the beneficiaries and business and governmental security end-users. Key technologies and procedural aspects covered by the project include: Container and goods/inventory, authentication, traceability, inspection and monitoring technologies; Risk assessment systems and models; Information transfer systems; Intermodal transport security; Modernisation of customs procedures; Protection of supply chain infrastructure. As the main output, LOGSEC will identify the most relevant/promising research areas and research gaps, which should be addressed in the follow-up demonstration project. The LOGSEC project team consists of organisations with in depth experience in European and global supply chain security research and technology analysis and end-user partners representing a broad set of European shippers and logistics operators and customs administrations. The methodology consists of literature and project reviews; expert interviews; user surveys; user workshops. Background theory will be drawn from supply chain and logistics management; security management; and crime prevention theories. Lessons learnt in other regions, including North and South America and Asia will be exploited during the course of the project. Links to key parallel projects will be established, including demonstrations in Integrated border management (Security) and China-EU secure trade lane (Transportation); related projects with the World Customs Organisation and the World Bank amongst others.

Keywords: logistics,supply chain,security,european freight
Operations management and demand-based approaches to healthcare outcomes and cost-benefits research (MANAGED OUTCOMES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Finland,Netherlands,Germany,Spain,Belgium,France,Germany,Greece,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2012-12-31
Duration (months): 36.0
Total project cost (EUR): 3630469.2
EU funding (EUR): 2972081.75
Participants: 10
Project status: CLOSED

The MANAGED OUTCOMES proposal explores the assumption that healthcare outcomes and costs are affected by the efficiency of service production, the time/location constrained regional structure of healthcare delivery, and the degree to which people are empowered to participate in the co-production of their care. These relationships are insufficiently understood and need to be studied to meet the objectives of the new European health strategy. More optimized health systems should be planned on the grounds of citizens’ expectations for both effective outcomes, and for access and quality of healthcare delivery. The MANAGED OUTCOMES aims to generate the necessary scientific basis to underpin informed policy decisions. The expected impacts of the project on several levels of beneficiaries include the aim to advance the field of health systems research by promoting active dialogue between service research, operations management, health economics, and clinical medicine. This requires two types of actionable knowledge for policy makers: a) the cost impact and interrelationships of improved quality of care, efficiency and accessibility, and b) the cost impact of improved outcomes partly achieved with empowered customers acting as co-producers of their care. Practical impacts are a) methods for comparing and benchmarking healthcare production and distribution practices across Europe, to further the exchange of best practices across cultural contexts, b) demand-based tools for designing healthcare systems, and c) knowledge on the impacts of different service channels on health outcomes and cost-benefits. These results contribute to healthcare reform. This project aims to enhance the cooperation between European healthcare operations scholars to further promote integration and excellence of European healthcare systems research. The principal research method is comparative case studies and the project aims to develop scenarios and models of future healthcare systems.

Keywords: outcomes,healthcare service production system,health system,efficiency,operations management,model,scenario,cost-benefit,management
Scientific Approach to Finding Indicators of and REsponses to Radicalisation (SAFIRE)

Framework: FP7 — Cooperation
Programme: Security
Destination: Security and society
Action type: Collaborative project
Countries involved: Netherlands,Portugal,Israel,France,United Kingdom,Netherlands,Netherlands,Italy
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-06-01
End date: 2013-11-30
Duration (months): 42.0
Total project cost (EUR): 3618945.86
EU funding (EUR): 2906600.95
Participants: 11
Project status: CLOSED

The goal of SAFIRE is to improve fundamental understanding of radicalisation processes and use this knowledge to develop principles to improve (the implementation) of interventions designed to prevent, halt and reverse radicalisation. SAFIRE will develop a process model of radicalisation, describing the process from moderation to extremism, based on a non-linear dynamic systems approach and a typology of radical groups. This is an innovative approach that has not been explicitly applied to this area up until now. Principles regarding interventions will be developed in close concert with the models, and will be applied in a longitudinal, empirical study. Important aspects of radicalisation that will also be addressed are: the relationship between national culture and radicalisation, radicalisation on the Internet, and defining observable indicators of the radicalisation process. The main deliverable is a CD containing on one hand a detailed description of the work done in SAFIRE and on the other an interactive, accessible overview of the project designed for quick, user-friendly accessibility to the main points. Envisaged end-users are policy makers, researchers in the field of radicalisation and professionals who work with high-risk individuals. The results of this project will increase the understanding of both conceptual aspects of radicalisation (e.g. the psycho-social dynamics of radical groups and individuals), and practical characteristics and modus operandi of radical groups (e.g. recruitment techniques). In addition, the results will increase understanding of field efforts and interventions – when, why and how they work – thus helping focus the allocation of resources and the implementation of interventions.

Keywords: radicalisation,process model,typology of radical groups,culture,empricial study,media